- Home
- MBIO vs PRPO Comparison
MBIO vs PRPO Comparison
Compare MBIO & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBIO
- PRPO
- Stock Information
- Founded
- MBIO 2015
- PRPO N/A
- Country
- MBIO United States
- PRPO United States
- Employees
- MBIO N/A
- PRPO N/A
- Industry
- MBIO Biotechnology: Pharmaceutical Preparations
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- MBIO Health Care
- PRPO Industrials
- Exchange
- MBIO Nasdaq
- PRPO Nasdaq
- Market Cap
- MBIO 4.7M
- PRPO 17.1M
- IPO Year
- MBIO N/A
- PRPO N/A
- Fundamental
- Price
- MBIO $2.49
- PRPO $14.85
- Analyst Decision
- MBIO
- PRPO
- Analyst Count
- MBIO 0
- PRPO 0
- Target Price
- MBIO N/A
- PRPO N/A
- AVG Volume (30 Days)
- MBIO 17.5M
- PRPO 17.6K
- Earning Date
- MBIO 08-12-2025
- PRPO 08-12-2025
- Dividend Yield
- MBIO N/A
- PRPO N/A
- EPS Growth
- MBIO N/A
- PRPO N/A
- EPS
- MBIO N/A
- PRPO N/A
- Revenue
- MBIO N/A
- PRPO $20,029,000.00
- Revenue This Year
- MBIO N/A
- PRPO N/A
- Revenue Next Year
- MBIO N/A
- PRPO N/A
- P/E Ratio
- MBIO N/A
- PRPO N/A
- Revenue Growth
- MBIO N/A
- PRPO 26.67
- 52 Week Low
- MBIO $0.89
- PRPO $3.90
- 52 Week High
- MBIO $24.00
- PRPO $16.89
- Technical
- Relative Strength Index (RSI)
- MBIO 59.93
- PRPO 68.17
- Support Level
- MBIO $2.62
- PRPO $15.00
- Resistance Level
- MBIO $3.68
- PRPO $16.89
- Average True Range (ATR)
- MBIO 0.59
- PRPO 1.13
- MACD
- MBIO 0.15
- PRPO 0.33
- Stochastic Oscillator
- MBIO 27.30
- PRPO 67.99
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.